LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

SektorTervishoid

2.93 -2.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.85

Max

3.03

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+110.3% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	81M 203M
Eelmine avamishind	5.91
Eelmine sulgemishind	2.93

Uudiste sentiment

By Acuity

50%

166 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 23:58 UTC

Tulu

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. mai 2026, 22:57 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. mai 2026, 23:52 UTC

Tulu

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. mai 2026, 23:11 UTC

Tulu

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. mai 2026, 23:06 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. mai 2026, 23:05 UTC

Tulu

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. mai 2026, 23:04 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. mai 2026, 23:02 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. mai 2026, 22:42 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. mai 2026, 22:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 22:32 UTC

Tulu

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie: 68% of FY Income From International >MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. mai 2026, 22:29 UTC

Tulu

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. mai 2026, 22:26 UTC

Tulu

Macquarie to End Share Buyback Extended in November>MQG.AU

7. mai 2026, 22:25 UTC

Tulu

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

110.3% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD 110.3%

Kõrge 9 USD

Madal 4 USD

Põhineb 5 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

166 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.